Weight-loss version of smegerutide Chinese manual updated to include cardiovascular benefit results
2025-04-21 07:52:10
On April 21, the reporter learned from Novo Nordisk that the National Drug Administration of China (NMPA) approved the update of the instructions of Novo Inglein (weight-reduced version of smegerutide 2.4mg). This update is based on the main results of SELECT (Smegerutide Cardiovascular Outcomes Trial in Overweight or Obese Patients): < b > In overweight or obese adult patients with diagnosed cardiovascular disease without diabetes, Novo Inglein reduced the risk of major adverse cardiovascular events (MACE, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) by 20%.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
